SRRK Stock Forecast & Price Target

Scholar Rock Holding is supported by a rare but important combination of first-in-class FDA approval and a broad SMA label that can reach nearly all of the roughly 6,600 U.S. patients already on SMN2-targeting therapy, which materially expands the commercial opportunity. The approval of ISEMBYLD was backed by Phase 3 SAPPHIRE data showing a clinically meaningful 2.2-point HFMSE improvement, while very high continuation into ONYX and broad prescriber engagement across about 140 treatment centers and 2,600 physicians reduce adoption risk. Financially, higher net pricing expectations of about $310,000 per patient per year lifted projected 2035 revenue to $2.2 billion, and the company’s wholly owned approved therapy gives it a rare standalone mid-cap biotech profile with blockbuster potential.

Scholar Rock Holding is facing a fragile thesis because the osteoporotic fracture pattern being cited as supportive of apitegromab appears potentially non-unique, weakening confidence that its efficacy signal is truly differentiated. Investor concerns are compounded by payer-duration risk and the possibility that insurers may treat Isembyld differently from SMN modifiers, while the company still faces meaningful regulatory, safety, and pricing-reform risks that could disrupt reimbursement and European sales. Even with recent approval, the business remains early-stage and capital intensive, with risk of trial failure, competitive pressure from better-resourced peers, and possible additional equity financing before any durable earnings base emerges.